文献速递类风湿关节炎

慢性肾病患者中一线生物制剂改善病情抗风湿药治疗类风湿关节炎的疗效与安全性

Efficacy and safety of first-line biological DMARDs in rheumatoid arthritis patients with chronic kidney disease.
PubMed 文献 · Ann Rheum Dis · 2024-09-30

这项回顾性队列研究纳入2004至2021年两家医院首次使用生物制剂改善病情抗风湿药(bDMARDs)的425例类风湿关节炎(RA)合并慢性肾病(CKD)患者,按肾功能和bDMARD种类分层。结果显示各类bDMARD在肾功能较低组中36个月药物留存率总体得以维持,但TNFα抑制剂在eGFR<30 mL/min/1.73 m2组留存率显著降低;IL-6抑制剂在该组留存率最高、因无效停药最少(HR 0.11,95%CI 0.02至0.85,p=0.03)。

要点

  • 425例RA合并CKD患者中,各bDMARD在肾功能较低组的36个月留存率总体得以维持。
  • eGFR<30 mL/min/1.73 m2组TNFα抑制剂留存率显著降低,IL-6抑制剂留存率最高。
  • eGFR<30 mL/min/1.73 m2组IL-6抑制剂因无效停药最少,HR 0.11(95%CI 0.02至0.85,p=0.03)。

核心结论

  • bDMARDs在RA合并CKD患者(包括血液透析患者)中显示出有效且安全的特征。
  • IL-6抑制剂在eGFR<30 mL/min/1.73 m2患者中药物留存率显著更高、因无效停药更少。
  • 与其他bDMARDs相比,IL-6抑制剂单药治疗更有效。

研究设计与样本

  • 回顾性队列研究,纳入2004至2021年两家医院首次处方bDMARDs的425例RA患者。
  • 按肾功能和bDMARD种类(TNFα抑制剂、IL-6抑制剂、CTLA4-Ig)分类。
  • 主要结局为36个月药物留存率,次要结局包括DAS28-CRP/ESR变化、泼尼松龙剂量及停药原因。

主要发现

  • 36个月药物留存率按eGFR(≥60、30-60、<30 mL/min/1.73 m2)分别为:全部bDMARDs 45.2%、32.0%、41.4%,TNFα抑制剂45.3%、28.2%、34.0%,IL-6抑制剂47.4%、66.7%、71.4%,CTLA-4Ig 50.0%、31.3%、33.3%。
  • 即使在肾功能较低组,bDMARDs的药物留存率总体得以维持,但eGFR<30 mL/min/1.73 m2组TNFα抑制剂留存率显著降低。
  • eGFR<30 mL/min/1.73 m2组IL-6抑制剂留存率最高、因无效停药率最低(HR 0.11,95%CI 0.02至0.85,p=0.03)。
  • 所有bDMARDs在各组均改善DAS28-CRP/ESR并降低泼尼松龙剂量。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy and safety of first-line biological disease-modifying antirheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (RA) with chronic kidney disease (CKD), including those undergoing haemodialysis (HD). METHODS: This retrospective cohort study included 425 patients with RA prescribed their first bDMARDs at two hospitals from 2004 to 2021. Patients were categorised by kidney function and bDMARD modality (TNFα inhibitors (TNFαis), interleukin-6 inhibitors (IL-6is), cytotoxic T-lymphocyte antigen-4 immunoglobulin (CTLA4-Ig)). The primary outcome was the 36-month drug retention rate, with secondary outcomes including changes in Disease Activity Score 28 (DAS28)-C reactive protein (CRP)/erythrocyte sedimentation rate (ESR), prednisolone dosage and reasons for discontinuation. RESULTS: The 36-month drug retention rates by estimated glomerular filtration rate (eGFR) (≥60, 30-60, <30 mL/min/1.73 m2) were as follows: all bDMARDs (45.2%, 32.0%, 41.4%), TNFαis (45.3%, 28.2%, 34.0%), IL-6is (47.4%, 66.7%, 71.4%) and CTLA-4Ig (50.0%, 31.3%, 33.3%). Even in groups with lower kidney function, the drug retention rate of bDMARDs was generally maintained. However, the retention rate of TNFαis was significantly lower in patients with eGFR <30 mL/min/1.73 m2. IL-6is showed the highest retention rate and the lowest discontinuation rate due to ineffectiveness in this group (HR 0.11, 95% CI 0.02 to 0.85, p=0.03). All bDMARDs improved DAS28-CRP/ESR and reduced prednisolone dosage across all groups. CONCLUSION: bDMARDs demonstrated effective and safe profiles in patients with RA with CKD, even among patients on HD. In particular, IL-6is had a significantly higher drug retention rate in patients with an eGFR of <30 mL/min/1.73 m2 and fewer discontinuations due to ineffectiveness. IL-6is were more efficacious as monotherapy compared with the other bDMARDs.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Yoshimura Y, Yamanouchi M, Mizuno H, et al. Efficacy and safety of first-line biological DMARDs in rheumatoid arthritis patients with chronic kidney disease. Ann Rheum Dis. 2024. PMID: 38964755. doi:10.1136/ard-2024-225914

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。